Unknown

Dataset Information

A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.


ABSTRACT: Acute myeloid leukemia (AML) is a rapidly progressive hematological malignancy that is difficult to cure. The prognosis is poor and treatment options are limited in case of relapse. A comprehensive assessment of current disease burden and the clinical efficacy of non-intensive therapies in this population are lacking. We conducted two systematic literature reviews (SLRs). The first SLR (disease burden) included observational studies reporting the incidence and economic and humanistic burden of relapsed/refractory (RR) AML. The second SLR (clinical efficacy) included clinical trials (phase II or later) reporting remission rates (complete remission [CR] or CR with incomplete hematologic recovery [CRi]) and median overall survival (mOS) in patients with RR AML or patients with de novo

SUBMITTER: Oliva EN 

PROVIDER: S-EPMC8446831 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature